RV-001
Gene-Agnostic Retinitis Pigmentosa
Phase I/IIActive (First patient dosed Feb 2025)
Key Facts
Indication
Gene-Agnostic Retinitis Pigmentosa
Phase
Phase I/II
Status
Active (First patient dosed Feb 2025)
Company
About Restore Vision
Developing gene-agnostic visual restoration therapies for inherited retinal diseases like retinitis pigmentosa.
View full company profile